Investigating the link between TDP-43 inclusions and double stranded RNA in Alzheimer's and frontotemporal dementia
Defining the pathogenic relationship of TDP-43 inclusions and cytoplasmic double stranded RNA in AD and FTD
This study is looking at how certain proteins and molecules in the brains of people with Alzheimer's and frontotemporal dementia might be connected, to help us understand more about what causes memory problems in these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10502780 on NIH RePORTER |
What this research studies
This research focuses on understanding how TDP-43 inclusions, which are found in many Alzheimer's disease (AD) patients, relate to the presence of double stranded RNA (dsRNA) in the brain. The study aims to explore whether these inclusions and dsRNA are found together in brain tissues from individuals with AD and frontotemporal dementia (FTD). Using advanced microscopy techniques, researchers will analyze brain samples to uncover the potential mechanisms behind cognitive decline associated with these conditions. By examining the relationship between TDP-43 and dsRNA, the research hopes to shed light on the underlying pathology of these neurodegenerative diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or frontotemporal dementia, particularly those exhibiting cognitive decline.
Not a fit: Patients with other forms of dementia or neurodegenerative diseases that do not involve TDP-43 inclusions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights into the mechanisms of cognitive decline in Alzheimer's and FTD, potentially guiding future therapeutic strategies.
How similar studies have performed: Previous research has indicated a correlation between TDP-43 inclusions and cognitive decline, suggesting that this approach may yield valuable insights into these conditions.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Albers, Mark W — Harvard Medical School
- Study coordinator: Albers, Mark W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.